Relentless Health Value
Cash Pay From the Pharma Manufacturer Point of View, With Ophelia Johnson
Why It Matters
Understanding cash‑pay dynamics is crucial as more patients seek affordable access to high‑cost drugs like GLP‑1s, and manufacturers must adapt to regulatory and market pressures. This episode equips pharma leaders and health‑plan sponsors with the knowledge to design sustainable, transparent pricing models that can improve patient adherence and reduce reliance on opaque PBM rebates.
Key Takeaways
- •Pharma uses cash‑pay coupons to bypass PBMs, lower cost
- •IRA and PBM reforms pressure manufacturers toward transparent pricing
- •Managing new channel partners requires robust gross‑to‑net controls
- •Telehealth platforms add distribution complexity but enable direct patient purchases
- •Revenue leakage risk rises without disciplined operational infrastructure
Pulse Analysis
The cash‑pay, or self‑pay, model has shifted from niche discount cards to a mainstream channel for GLP‑1 and other high‑cost drugs. By presenting a transparent price at the pharmacy checkout, manufacturers bypass the PBM rebate black box and pass savings directly to patients. Legislative pressure from the Inflation Reduction Act and ongoing PBM reform lawsuits have forced drug makers to rethink pricing. Meanwhile, only about half of new GLP‑1 prescriptions receive insurance approval, driving patient demand for a faster, out‑of‑network purchase path. This shift also encourages manufacturers to experiment with direct‑to‑consumer digital outreach.
Implementing cash‑pay programs adds operational complexity. Manufacturers must recalculate gross‑to‑net margins, ensure unit‑economics stay positive, and contract with new intermediaries such as GoodRx. These coupon providers receive a flat fee—often a few dollars per script—to administer discounts and keep pharmacies whole, replacing traditional PBM dispense fees. When a telehealth platform also dispenses the drug, extra variables appear: shipping costs, credit‑card fees, and separate make‑whole agreements. Additionally, data sharing agreements must comply with HIPAA and state privacy rules. Without disciplined back‑office systems, revenue leakage can quickly erode profitability.
For pharma executives, cash‑pay offers a way to boost adherence while preserving price transparency. Successful programs align patients, employers, and plan sponsors by lowering out‑of‑pocket costs and avoiding costly prior‑auth delays. The upside depends on precise pricing models, clear contracts with coupon or telehealth partners, and robust analytics to monitor margins. Investing in real‑time pricing dashboards further safeguards against unexpected margin swings. Companies that master these elements can turn the two‑sided market into a competitive advantage; those that ignore operational detail risk profit erosion and strained ecosystem relationships.
Episode Description
Only roughly 50% of new GLP-1 prescriptions were getting approved for coverage in 2023. From a plan sponsor's seat, that looks like pharmacy trend spiking 9%, 12%, even 20% year over year. From a pharma manufacturer's seat, it's half their prescriptions not getting filled. Same market, opposite problems — and that's exactly the lens this episode flips on.
In this episode, Stacey Richter speaks with Ophelia Johnson, who built new business channels for a pharmaceutical manufacturer that created the GLP-1 boom and has since launched a consulting practice at e-fi.works, about how cash pay models work from the inside — coupon platforms, telehealth channels, white label pharmacy models, and employer carve-outs — and where the new fees are hiding.
WHAT YOU'LL LEARN
✅ How the Inflation Reduction Act, PBM legal scrutiny, drug shortages, and the compounding bypass converged with ~50% GLP-1 prior auth denial rates in 2023 to push pharma into building cash pay channels that cut the PBM out entirely
✅ How the savings coupon model works: manufacturer buys the patient down to a flat transparent cash price via platforms like GoodRx, pays a fixed per-script fee instead of a PBM rebate, and the coupon platform makes the pharmacy whole — transparent math, no black box
✅ How the telehealth channel and white label pharmacy models extend the distribution chain beyond retail — and why shipping costs, credit card fees, dispensing fees, and new supply chain partners create gross-to-net and revenue leakage risk for manufacturers not built for it
✅ Why "direct to employer" is a misnomer: PBM contracts prohibit pharma from selling directly to self-insured employers, so third-party transparent administrators have emerged — but plan sponsors need to run the math first, given ERISA complications and PBM contract leverage
✅ How PBMs are now charging fees for hub-like patient support services to manage the exact prior auth complexity they created — a Whack-a-Mole shift of profitability that everyone needs to map before signing anything
✅ Ophelia's three-part practical advice: map the full patient journey and all ecosystem player incentives before building any new model (pharma); treat affordability as a clinical risk factor (clinicians); demand auditable medication abandonment data rather than settling for rebate yield metrics (plan sponsors)
WHY THIS MATTERS
If collaboration is the next innovation, everyone has to understand the incentives of every player in the ecosystem — not just their own. The same 50% of unfilled GLP-1 prescriptions that looks like runaway pharmacy trend from a plan sponsor's seat looks, from a manufacturer's seat, like half their market going dark — and both sides are making moves that affect each other. Understanding those moves, where fees are being layered on, and when fair profit tips into what Stacey calls profiteering is what this episode maps.
TUNE IN NEXT WEEK
Next week is the 401-level companion to this one — Stacey goes solo on the PBM and GPO contracting mechanics behind why cash pay became a thing, and why cheaper or better drugs can inexplicably end up off formulary or buried under prior auth.
=== LINKS ===
🔗 Show Notes with all mentioned links:
https://cc-lnk.com/EP516
✉️ Enjoy this podcast? Subscribe to the free weekly newsletter:
https://relentlesshealthvalue.com/join-the-relentless-tribe
🫙 Support the podcast with a small donation to the Tip Jar:
https://relentlesshealthvalue.com/join-the-relentless-tribe
📺 Subscribe to our YouTube channel
https://www.youtube.com/@RelentlessHealthValue
🎤 Listen on Apple Podcasts
https://podcasts.apple.com/us/podcast/feed/id892082003?ls=1
🎤 Listen on Spotify
https://open.spotify.com/show/6UjgzI7bScDrWvZEk2f46b
=== CONNECT WITH THE RHV TEAM ===
✭ LinkedIn https://www.linkedin.com/company/relentless-health-value/
✭ Threads https://www.threads.net/@relentlesshealthvalue/
✭ Bluesky https://bsky.app/profile/relentleshealth.bsky.social
✭ X https://twitter.com/relentleshealth/
00:00 Introduction to this episode.
02:02 LinkedIn post by David Alderman.
06:13 LinkedIn post by Ann Lewandowski.
07:05 Backgrounder LinkedIn post by Madelaine Feldman, MD.
08:07 The conversation with Ophelia Johnson.
08:14 What is cash pay?
08:59 Why is this a thing, and how did we get here?
10:47 LinkedIn post by Bryce Platt, PharmD, on prior authorization reform.
12:28 The different ways that a patient could go about receiving and paying for their drug.
13:22 What's going on behind the scenes between GoodRx and the pharma manufacturer.
17:02 What dispense fees are and how they work.
17:41 A sidenote about next week's episode.
18:00 AEE13 with Ge Bai, PhD, CPA.
19:03 EP439 with Luke Slindee, PharmD.
20:03 A sidenote about the pharma manufacturer POV.
21:44 The pharma supply chain in telehealth.
25:27 Why claims validation has never been more important.
28:19 Where do employers fit in all of this?
32:45 Where does it make sense to consider these alternative business models in lieu of the risks?
35:04 Why mapping the incentives is important.
38:42 Ophelia's advice to pharma manufacturers.
40:41 Ophelia's advice to plan sponsors.
41:32 EP426 with Nina Lathia, RPh, MSc, PhD.
42:46 More of Ophelia's advice to payers.
Comments
Want to join the conversation?
Loading comments...